Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA

Join us live or online to listen to current clinical guidance and perspectives on the optimal use of BCMA-targeted agents in myeloma from recognized experts and ask your questions during panel discussions.

Not an official event of the SOHO 2021 Annual Meeting. Not sponsored or endorsed by the Society of Hematologic Oncology.


Welcome, Introduction, and Baseline Assessment

Mechanisms of Action and Rationale for Anti-BCMA Therapy in MM

Antibody–Drug Conjugates Targeting BCMA

Anti-BCMA CAR T-Cell Therapy

Bispecific T-Cell Engagers and Bispecific Monoclonal Antibodies

Program will include patient case examples and clinical scenarios for integrating BCMA-targeted agents into clinical practice, and time for you to ask questions and hear answers from the experts.


Date / Time
Event Details


Program Director
Sagar Lonial, MD

Professor and Chair 
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Suzanne Lentzsch, MD, PhD

Director, Multiple Myeloma and Amyloidosis Program
Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California

Goal Statement
The goal of this activity is to improve learners’ knowledge of and competence in applying practice-changing clinical data and expert recommendations to integrate the use of BCMA-targeted agents for their patients with multiple myeloma.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Understand the clinical rationale for incorporating BCMA-targeted agents into the treatment plan for patients with multiple myeloma
  • Differentiate and compare the available efficacy, safety, and tolerability data among the different BCMA-targeted therapies in patients with multiple myeloma
  • Identify patients with multiple myeloma who are likely to benefit from treatment with currently available BCMA-targeted therapy
  • Monitor and mitigate potential adverse events from anti-BCMA therapy in patients with multiple myeloma, including ocular toxicity, cytokine release syndrome, and neurotoxicity
  • Select patients with relapsed/refractory multiple myeloma who would be eligible for enrollment on clinical trials of therapies targeting BCMA


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.